A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension
NCT ID: NCT04503733
Last Updated: 2022-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
48 participants
INTERVENTIONAL
2020-10-22
2023-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension
NCT05948644
Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension
NCT07177703
Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
NCT03926793
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
NCT06137742
Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
NCT06753981
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Q4W GMA301 IV injections (300 mg)
Drug: Q4W GMA301 IV injections (300 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301
Q4W GMA301 IV injections (300 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W placebo IV injections
Placebo is indistinguishable from GMA301.
Q4W GMA301 IV injections (600 mg)
Drug: Q4W GMA301 IV injections (600 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301
Q4W GMA301 IV injections (600 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W placebo IV injections
Placebo is indistinguishable from GMA301.
Q4W GMA301 IV injections (1000 mg)
Drug: Q4W GMA301 IV injections (1000 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301
Q4W GMA301 IV injections (1000 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W placebo IV injections
Placebo is indistinguishable from GMA301.
Q4W GMA301 IV injections (1800 mg)
Drug: Q4W GMA301 IV injections (1800 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301
Q4W GMA301 IV injections (1800 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W placebo IV injections
Placebo is indistinguishable from GMA301.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Q4W GMA301 IV injections (300 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W GMA301 IV injections (600 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W GMA301 IV injections (1000 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W GMA301 IV injections (1800 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W placebo IV injections
Placebo is indistinguishable from GMA301.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female, aged 18 to 75 years inclusive
2. WHO Group 1 PAH related to one of the following conditions:
1. Idiopathic
2. Heritable
3. Drugs or toxins-induced
4. Associated with connective tissue disease
5. Associated with congenital heart disease if subjects underwent surgical correction more than 12 months before Screening
3. Symptoms due to PAH are consistent with WHO functional class II- III
4. Have not taken endothelin receptor antagonists (ERAs) within 3 months before Randomization
5. Has been taking at least one oral PAH targeted drug that has been approved by local guidelines for at least 3 months before Screening with stable dosage and the disease did not worsen during this period per Investigator's judgment
6. Right heart catheterization (RHC) result meets below criteria when Screening:
1. Mean pulmonary arterial pressure (PAP) ≥25 mmHg
2. Pulmonary vascular resistance (PVR) \>3 Woods units
3. PA wedge pressure (PAWP) ≤15 mmHg
If a subject has undergone RHC within 3 months before Screening, the waveform results will serve as baseline data only if they meet the entry criteria and the RHC at Screening will not be repeated. In case PAWP cannot be well measured during RHC, left ventricular end diastolic pressure will be tested by left heart catheterization.
7. Has a six-minute walk test (6MWT) with distance between 150 to 450 meters at Screening
8. The dosage of digitalis drugs or L-arginine supplementation must be stable for at least 1 month before Screening, if applicable.
9. No new use of an IV diuretic, cardiotonic (positive inotropic agents), or vasoactive drug within 30 days before Screening
10. Both male and female subjects agree to use 2 medically acceptable methods of contraception (Appendix 4) throughout the entire study period from informed consent signing to 90 days after last dose, if the possibility of conception exists. Medically acceptable methods of contraception include oral, implantable, or injectable contraceptives (starting 2 months before dosing); diaphragm with vaginal spermicide; intrauterine device; condom and partner using vaginal spermicide; and surgical sterilization (6 months after surgery). Women who are surgically sterile or those who are postmenopausal for at least 2 years are not considered to be of childbearing potential. Eligible male and female subjects must agree not to participate in a conception process (i.e. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) during the study and for 90 days after the last dose of study drug.
11. Body weight no less than 40 kg at Screening
12. Able to understand and willing to sign the Informed Consent Form (ICF) and comply with the study procedures.
Exclusion Criteria
1. Diagnosed with WHO Group II, III, IV, V of PH
2. Use of calcium channel blockers within 1 month prior to Screening
3. Systolic blood pressure (SBP) \>160 mmHg or diastolic blood pressure (DBP) \>100 mmHg at Screening
4. SBP \<90 mmHg at Screening
5. Pulmonary function test: FEV1 \<60% of predicted, TLC \<60% of predicted, DLCO \<60% of predicted
6. History of pulmonary embolism as judged by the Investigator
7. Uncontrolled sleep apnea at the discretion of the Investigator
8. Limited full participation in the 6MWT due to arthritic, neuromuscular, vascular or other diseases unrelated to PAH
9. History of acute cardiovascular and/or cerebrovascular events within 6 months before Screening
10. Echocardiogram (ECHO) demonstrating at least one of the following at Screening:
1. LVEF \<50%
2. Mean end-diastolic left ventricular septal and posterior wall thickness of \>12 mm
3. Left atrial (LA) area on apical 4 chamber view \>20 cm2
4. LA volume \>55 mL
5. LA volume index \>34 mL/m2
6. Significant valvular heart disease including moderate or severe mitral or aortic stenosis with an aortic valve area \<1.0 cm2 or mitral valve area \<1.5 cm2, greater than moderate aortic or mitral regurgitation, greater than moderate tricuspid or pulmonic stenosis
11. Restrictive, dilated or hypertrophic cardiomyopathy or constrictive pericarditis
12. Using non-oral prostacyclin when Screening
13. Laboratory parameters during Screening:
1. Baseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 times the upper limit of normal (ULN) or total bilirubin ≥1.5 times ULN
2. Estimated glomerular filtration rate (eGFR) \<60 mL/min by Cockcroft-Gault formula
Online calculation available from https://www.kidney.org/professionals/KDOQI/gfr\_calculatorCoc
Cockcroft-Gault formula (1973):
Male: CCr=((l40-Age) × Weight)/(72×SCr)
Female: CCr={((l40-Age) × Weight)/(72×SCr)}× 0.85
CCr (creatinine clearance rate) = mL/min
Age = year
Weight = Kg
SCr (serum creatinine) = mg/dL
3. Hemoglobin concentration ≤100 g/L at Screening
14. QTc interval by Fridericia's criteria (QTcF) ≥500 msec at Screening
15. Malignancy within 5 years before Screening visit (with the exception of localized non-metastatic basal cell carcinoma of the skin, non-metastatic carcinoma of the prostate or in-situ carcinoma of the cervix excised with curative results)
16. Alcohol or drug abuse within 1 year before Screening
17. A psychiatric, addictive or other disorder that compromises the ability to give informed consent for participating in this study
18. History of organ transplantation
19. Pregnant or nursing females
20. History of HIV
21. Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), or HIV antibody (HIV-ab)
22. Enrolled in another interventional study within 30 days before Screening
23. Any condition that, in the opinion of the Investigator, prevents a potential subject from safely participating in the study
24. Start a new exercise program or participate in any unusually strenuous physical exertion within 6 weeks prior to Screening.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gmax Biopharm LLC.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hua Yao
Role: PRINCIPAL_INVESTIGATOR
Guangdong Provincial People's Hospital
Lan Wang
Role: PRINCIPAL_INVESTIGATOR
Shanghai Pulmonary Hospital, Shanghai, China
Wei Huang
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital of Chongqing Medical University
Zaixin Yu
Role: PRINCIPAL_INVESTIGATOR
Xiangya Hospital of Central South University
Fenling Fan
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital Xi'an Jiaotong University
Zhicheng Jing
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital - Dongcheng District
Aaron Waxman
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Peking Union Medical College Hospital - Dongcheng District
Beijing, , China
Xiangya Hospital, Central South University
Changsha, , China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, , China
Guangdong General Hospital
Guangzhou, , China
Shanghai Pulmonary Hospital
Shanghai, , China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Aaron Waxman
Role: primary
Zhicheng Jing
Role: primary
Zaixin Yu
Role: primary
Wei Huang
Role: primary
Hua Yao
Role: primary
Lan Wang
Role: primary
Fenling Fan
Role: primary
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GETA_MAD_01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.